Canesten 200mg Pessary *
Pharmacy Only: Non-prescription
Legal Category:Supply through pharmacy only
*Additional information is available within the SPC or upon request to the company
Summary of Product Characteristics last updated on medicines.ie:10/4/2015
Canesten 200mg Pessary.
Each pessary contains Clotrimazole 200mg
Excipients – Contains Lactose Monohydrate 602 – 610mg
For a full list of excipients, see section 6.1
White biconvex tablets with the name 'Bayer' engraved on one side and 'NR' on the other.
4.1 Therapeutic indications
Canesten 200mg Pessaries are recommended for the treatment of candidal vaginitis.
4.2 Posology and method of administration
Canesten 200mg Pessaries should be inserted intravaginally, as high as possible, using the applicator supplied.
Adults and children of 12 years of age and older:
Insert one pessary daily, preferably at night, before going to bed, for three consecutive days.
If symptoms persist for more than 7 days the patient may have a medical condition that requires treatment by a doctor.
The treatment can be repeated if necessary, however, recurrent infections may indicate an underlying medical cause.
Patient should seek medical advice if symptoms return within 2 months.
If the labia and adjacent areas are simultaneously infected, local treatment with an external cream should also be given in addition to the intravaginal treatment (combination treatment).
Canesten pessaries need moisture in the vagina in order to dissolve completely, otherwise undissolved pieces of the pessary might crumble out of the vagina. Pieces of undissolved pessary may be noticed by women who experience vaginal dryness. To help prevent this it is important that the pessary is inserted as high as possible into the vagina at bedtime.
Treatment during the menstrual period should not be performed due to the risk of the pessary being washed out by the menstrual flow. The treatment should be finished before the onset of menstruation.
Do not use tampons, intravaginal douches, spermicides or other vaginal products while using this product.
Avoidance of vaginal intercourse is recommended in case of vaginal infection while using this product because your partner could become infected.
Children under 12 years of age:
As this product is administered with a vaginal applicator, paediatric usage is not recommended.
To insert the pessary:
1. Pull out plunger until it stops. Place pessary into the applicator.
2. Insert applicator containing the pessary carefully as deeply as is comfortable into the vagina. (This is best done with the patient lying on her back with the knees bent up.)
3. Push plunger until it stops, thereby depositing the pessary into the vagina. Remove the applicator.
4. After use, remove plunger completely by pulling it out of the applicator. Then wash it in warm (not boiling) soapy water, rinse and dry carefully.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1..
4.4 Special warnings and precautions for use
Medical advice should be sought if this is the first time the patient has experienced symptoms of candidal vaginitis.
Before using Canesten 200mg Pessaries, medical advice must be sought if any of the following are applicable:
- More than two infections of candidal vaginitis in the last 6 months.
- Previous history of a sexually transmitted disease or exposure to partner with sexually transmitted disease.
- Pregnancy or suspected pregnancy.
- Aged under 12 or over 60 years.
- Known hypersensitivity to imidazoles or other vaginal antifungal products.
Canesten 200mg Pessaries should not be used if the patient has any of the following symptoms whereupon medical advice should be sought:
- Irregular vaginal bleeding
- Abnormal vaginal bleeding (vaginal haemorrhage) or a bloodstained discharge.
- Vulval or vaginal ulcers, blisters or sores.
- Lower abdominal pain or dysuria.
- Any adverse events such as redness, irritation or swelling associated with the treatment.
- Fever (temperature of 38°C or above) or chills
- Nausea or vomiting.
- Foul smelling vaginal discharge.
- Back pain.
- Associated shoulder pain.
Avoid contact with eyes and do not swallow.
All possibly infected areas should be treated at the same time.
4.5 Interaction with other medicinal products and other forms of interaction
Laboratory tests have suggested that, when used together, this product may cause damage to latex contraceptives. Consequently, the effectiveness of such contraceptives may be reduced. Patients should be advised to use alternative precautions for at least five days after using this product.
Concomitant medication with vaginal clotrimazole and oral tacrolimus (FK-506; immunosuppressant) might lead to increased tacrolimus plasma levels and similarly with sirolimus. Patients should thus be thoroughly monitored for symptoms of tacrolimus or sirolimus overdosage, if necessary by determination of the respective plasma levels.
4.6 Fertility, pregnancy and lactation
No human studies of the effects of clotrimazole on fertility have been performed, however, animal studies have not demonstrated any effects of the drug on fertility.
There are limited amount of data from the use of clotrimazole in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of clotrimazole during the first trimester of pregnancy.
During pregnancy the treatment should be carried out with clotrimazole vaginal tablets, since these can be inserted without using an applicator.
Available pharmacodynamic/toxicological data in animals have shown excretion of clotrimazole/metabolites in milk (see section 5.3). Breast-feeding should be discontinued during treatment with clotrimazole.
4.7 Effects on ability to drive and use machines
The medication has no or negligible influence on the ability to drive or use machinery.
4.8 Undesirable effects
The following adverse reactions have been identified during post-approval use of Clotrimazole. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.
Immune system disorders
Allergic reaction (ME) with symptoms such as dyspnea (PT), hypotension (PT), syncope (PT), and urticaria (ME),
Reproductive system and breast disorders
Vulvovaginal discomfort (PT), edema (PT), burning (PT), genital peeling, irritation, pruritus (ME), pelvic pain (PT), rash (ME), vaginal haemorrhage (PT), erythema (PT).
Abdominal pain (ME)
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: firstname.lastname@example.org.
In the event of accidental oral ingestion, routine measures such as gastric lavage should be performed only if clinical symptoms of overdose become apparent (e.g. dizziness, nausea or vomiting).
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Gynaecological antiinfectives and antiseptics – imidazole derivatives.
ATC Code: G01AF02
Mechanism of Action
Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the cytoplasmic membrane.
Clotrimazole has a broad antimycotic spectrum of action in vitro and in vivo, which includes dermatophytes, yeasts, moulds, etc.
Under appropriate test conditions, the MIC values for these types of fungi are in the region of less than 0.062 – 8.0 μg/ml substrate. The mode of action of clotrimazole is fungistatic or fungicidal depending on the concentration of clotrimazole at the site of infection. In vitro activity is limited to proliferating fungal elements; fungal spores are only slightly sensitive.
In addition to its antimycotic action, clotrimazole also acts on gram-positive microorganisms (streptococci/staphylococci/ Gardnerella vagiinalis) and gram-negative microorganisms (Bacteroides/). It has no effect on lactobacilli.
In vitro, clotrimazole inhibits the multiplication of Corynebacteria and gram-positive cocci – with the exception of enterococci – in concentrations of 0.5 – 10 μg/ml substrate.
Primarily resistant variants of sensitive fungal species are very rare; the development of secondary resistance by sensitive fungi has so far only been observed in very isolated cases under therapeutic conditions.
5.2 Pharmacokinetic properties
Pharmacokinetic investigations after vaginal application have shown that only a small amount of clotrimazole (3 – 10% of the dose) is absorbed. Due to the rapid hepatic metabolism of absorbed clotrimazole into pharmacologically inactive metabolites the resulting peak plasma concentrations of clotrimazole after vaginal applications of a 500mg dose were less than 10 ng/ml, reflecting that clotrimazole applied intravaginally does not lead to measurable systemic effects or side effects.
5.3 Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction and development.
6.1 List of excipients
Calcium lactate pentahydrate
Colloidal anhydrous silica
6.3 Shelf life
6.4 Special precautions for storage
Do not store above 25°C.
6.5 Nature and contents of container
Three pessaries are packed in a blister pack (foil 25 µm PA + 45 µm Al soft + 60 µm PVC) sealed with aluminium backing foil (foil 20 µm Al hard + 7 g/m2 HSL sealable to PVC/PVDC). An applicator is also provided.
The pessaries and applicator are enclosed in a cardboard carton.
6.6 Special precautions for disposal and other handling
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
Date of the first authorisation:
10 October 1979
Date of last renewal:
10 October 2009